doravirine; lamivudine; tenofovir disoproxil fumarate · Msd Merck Co · NDA 210807
Delstrigo
Earliest generic entry, as listed
29 Nov 2036
Blocked by patent: US 10603282, US 10842751.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10603282 | product | 29 Nov 2036 |
| US 10842751 | product | 29 Nov 2036 |
| US 8486975 | substance, product, use U-2629 | 30 Aug 2032 |
| US 8486975 | substance, product, use U-2395 | 30 Aug 2032 |
| US 8486975 | substance, product, use U-3307 | 30 Aug 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210807 · 001 · RLD | tablet, oral | 100MG;300MG;300MG | 29 Nov 2036 |